I am a die hard researcher in leukemia since last 1 year, though I am a clinician in practice. My guide does work on CML and he does abl-kinase domain mutations and we have got good results. I can ask him to help you out, but before that I would like to know what exactly is your aim and how deeply you are involved in your study. Is it kind of working you doing just because it will get you a degree or you are really interested in such things? Can I get to know what kind of samples you are dealing with? Are they cases directly put on IM or after treatment with some other drugs? Currently there is a debate going on as to whether these mutations pre-exist before starting IM or other TKIs or they are a result of such treatment. Again whether this is because such mutated strains are selected over non mutant ones or they just develop by the drugs themselves!

I deal with samples obtained from CML patients who come to the hospital for a regular check up and are on IM. Informed consent is obtained from each n every patient for this research. Patients who do not respond to IM have been administered alternative treatment but at this stage the treatment regime is not exactly the core of my concern but rather, the cause of “failure” of the treatment! I hope u hold a solution for my sequencing problems. I have tried to follow all the protocols published to the letter but have been unsuccessful thus far. Thanks for your support.